Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 615-636 |
| Number of pages | 22 |
| Journal | Bipolar disorders |
| Volume | 24 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 1 Sept 2022 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Bipolar disorders, Vol. 24, No. 6, 01.09.2022, p. 615-636.
Research output: Contribution to journal › Review article › Academic › peer-review
TY - JOUR
T1 - Can magnetic resonance imaging enhance the assessment of potential new treatments for cognitive impairment in mood disorders? A systematic review and position paper by the International Society for Bipolar Disorders Targeting Cognition Task Force
AU - Miskowiak, Kamilla W.
AU - Yalin, Nefize
AU - Seeberg, Ida
AU - Burdick, Katherine E.
AU - Balanzá-Martínez, Vicent
AU - Bonnin, Caterina del Mar
AU - Bowie, Christopher R.
AU - Carvalho, Andre F.
AU - Dols, Annemieke
AU - Douglas, Katie
AU - Gallagher, Peter
AU - Hasler, Gregor
AU - Kessing, Lars V.
AU - Lafer, Beny
AU - Lewandowski, Kathryn E.
AU - López-Jaramillo, Carlos
AU - Martinez-Aran, Anabel
AU - McIntyre, Roger S.
AU - Porter, Richard J.
AU - Purdon, Scot E.
AU - Schaffer, Ayal
AU - Sumiyoshi, Tomiki
AU - Torres, Ivan J.
AU - van Rheenen, Tamsyn E.
AU - Yatham, Lakshmi N.
AU - Young, Allan H.
AU - Vieta, Eduard
AU - Stokes, Paul R. A.
N1 - Funding Information: The authors thank the International Society for Bipolar Disorders executives and staff for their support of the ISBD Targeting Cognition Task Force. This work is non-funded. KWM holds a 5-year Lundbeck Foundation Fellowship (grant no. R215-2015-4121). TVR was supported by an NHMRC Early Career Fellowship (GNT1088785) and a Dame Kate Campbell Fellowship from the University of Melbourne. KD holds a Sir Charles Hercus Health Research Fellowship from the Health Research Council of New Zealand (grant no. 19/082). EV thanks the support of the Spanish Ministry of Science and Innovation (PI15/00283, PI18/00805) integrated into the Plan Nacional de I + D + I and co-financed by the ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM); the Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (2017 SGR 1365), the CERCA Programme, and the Departament de Salut de la Generalitat de Catalunya for the PERIS grant SLT006/17/00357. Funding Information: The authors thank the International Society for Bipolar Disorders executives and staff for their support of the ISBD Targeting Cognition Task Force. This work is non‐funded. KWM holds a 5‐year Lundbeck Foundation Fellowship (grant no. R215‐2015‐4121). TVR was supported by an NHMRC Early Career Fellowship (GNT1088785) and a Dame Kate Campbell Fellowship from the University of Melbourne. KD holds a Sir Charles Hercus Health Research Fellowship from the Health Research Council of New Zealand (grant no. 19/082). EV thanks the support of the Spanish Ministry of Science and Innovation (PI15/00283, PI18/00805) integrated into the Plan Nacional de I + D + I and co‐financed by the ISCIII‐Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM); the Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (2017 SGR 1365), the CERCA Programme, and the Departament de Salut de la Generalitat de Catalunya for the PERIS grant SLT006/17/00357. Funding Information: KWM has received consultancy fees from Janssen and Lundbeck in the past 3 years. RP uses computer software at no cost for research – provided by SBT‐pro and has received support for travel to educational meetings from Servier and Lundbeck. AS has received advisory or speaking fees from AbbVie, Janssen, Lundbeck, Otsuka, and Sunovion in the past 3 years. KD uses computer software at no cost for research provided by SBT‐pro. LVK has received consultancy fees from Lundbeck and Teva in the past 3 years. EV has received grants and served as consultant, advisor, or CME speaker for the following entities: AB‐Biotics, Abbott, Allergan, Angelini, Dainippon Sumitomo Pharma, Ferrer, Gedeon Richter, Janssen, Lundbeck, Otsuka, Sage, Sanofi‐Aventis, Sunovion, Takeda, all them unrelated to the present work. VBM has been a consultant, advisor, or Continuing Medical Education (CME) speaker over the last 3 years for the following companies: Angelini, Lundbeck, Nutrición Médica, and Otsuka. AY has conducted paid lectures and advisory boards for Allergan, AstraZeneca, Bionomics, BrainCells Inc., Bristol‐Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Lundbeck, Novartis, Otsuka Pharmaceutical Co., Pharmaceutica, Pfizer, Roche, Sanofi‐Aventis, Servier Laboratories, Sunovion, and Wyeth. He was lead Investigator for the EMBOLDEN Study (AstraZeneca), BCI Neuroplasticity Study, and Aripiprazole Mania Study, and has been involved in investigator‐initiated studies for AstraZeneca, Eli Lilly, and Wyeth. IJT has received has served as consultant for Lundbeck Canada, Sumitomo Dainippon and Community Living British Columbia. LNY has been on speaker/advisory boards for, or has received research grants from Alkermes, Allergan, AstraZeneca, Bristol Myers Squibb, CANMAT, CIHR, Dainippon Sumitomo Pharma, GSK, Janssen, Lilly, Lundbeck, Merck, Otsuka, Pfizer, Sanofi, Sunovion, and Teva. RM has received personal fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Allergan, Takeda, Neurocrine, Sunovion, Minerva, Intra‐Cellular, Abbvie, and Eisai and is a shareholder in the 420 Company and CEO of Champignon. AD, AC, BL, IS, MBJ, CRB, CMB, KEL, PG, CLJ, AMA, SEP, TS, and TVR report no conflict of interest. PRS reports non‐financial support from Janssen Research and Development LLC, personal fees, and non‐financial support from Frontiers in Psychiatry, personal fees from Allergan, a grant from H Lundbeck, grants, and non‐financial support from Corcept Therapeutics, outside the submitted work. Publisher Copyright: © 2022 The Authors. Bipolar Disorders published by John Wiley & Sons Ltd.
PY - 2022/9/1
Y1 - 2022/9/1
N2 - Background: Developing treatments for cognitive impairment is key to improving the functioning of people with mood disorders. Neuroimaging may assist in identifying brain-based efficacy markers. This systematic review and position paper by the International Society for Bipolar Disorders Targeting Cognition Task Force examines the evidence from neuroimaging studies of pro-cognitive interventions. Methods: We included magnetic resonance imaging (MRI) studies of candidate interventions in people with mood disorders or healthy individuals, following the procedures of the Preferred Reporting Items for Systematic reviews and Meta-Analysis 2020 statement. Searches were conducted on PubMed/MEDLINE, PsycInfo, EMBASE, Cochrane Library, and Clinicaltrials.gov from inception to 30th April 2021. Two independent authors reviewed the studies using the National Heart, Lung, Blood Institutes of Health Quality Assessment Tool for Controlled Intervention Studies and the quality of neuroimaging methodology assessment checklist. Results: We identified 26 studies (N = 702). Six investigated cognitive remediation or pharmacological treatments in mood disorders (N = 190). In healthy individuals, 14 studies investigated pharmacological interventions (N = 319), 2 cognitive training (N = 73) and 4 neuromodulatory treatments (N = 120). Methodologies were mostly rated as ‘fair’. 77% of studies investigated effects with task-based fMRI. Findings varied but most consistently involved treatment-associated cognitive control network (CCN) activity increases with cognitive improvements, or CCN activity decreases with no cognitive change, and increased functional connectivity. In mood disorders, treatment-related default mode network suppression occurred. Conclusions: Modulation of CCN and DMN activity is a putative efficacy biomarker. Methodological recommendations are to pre-declare intended analyses and use task-based fMRI, paradigms probing the CCN, longitudinal assessments, mock scanning, and out-of-scanner tests.
AB - Background: Developing treatments for cognitive impairment is key to improving the functioning of people with mood disorders. Neuroimaging may assist in identifying brain-based efficacy markers. This systematic review and position paper by the International Society for Bipolar Disorders Targeting Cognition Task Force examines the evidence from neuroimaging studies of pro-cognitive interventions. Methods: We included magnetic resonance imaging (MRI) studies of candidate interventions in people with mood disorders or healthy individuals, following the procedures of the Preferred Reporting Items for Systematic reviews and Meta-Analysis 2020 statement. Searches were conducted on PubMed/MEDLINE, PsycInfo, EMBASE, Cochrane Library, and Clinicaltrials.gov from inception to 30th April 2021. Two independent authors reviewed the studies using the National Heart, Lung, Blood Institutes of Health Quality Assessment Tool for Controlled Intervention Studies and the quality of neuroimaging methodology assessment checklist. Results: We identified 26 studies (N = 702). Six investigated cognitive remediation or pharmacological treatments in mood disorders (N = 190). In healthy individuals, 14 studies investigated pharmacological interventions (N = 319), 2 cognitive training (N = 73) and 4 neuromodulatory treatments (N = 120). Methodologies were mostly rated as ‘fair’. 77% of studies investigated effects with task-based fMRI. Findings varied but most consistently involved treatment-associated cognitive control network (CCN) activity increases with cognitive improvements, or CCN activity decreases with no cognitive change, and increased functional connectivity. In mood disorders, treatment-related default mode network suppression occurred. Conclusions: Modulation of CCN and DMN activity is a putative efficacy biomarker. Methodological recommendations are to pre-declare intended analyses and use task-based fMRI, paradigms probing the CCN, longitudinal assessments, mock scanning, and out-of-scanner tests.
UR - http://www.scopus.com/inward/record.url?scp=85138507774&partnerID=8YFLogxK
U2 - https://doi.org/10.1111/bdi.13247
DO - https://doi.org/10.1111/bdi.13247
M3 - Review article
C2 - 35950925
SN - 1398-5647
VL - 24
SP - 615
EP - 636
JO - Bipolar disorders
JF - Bipolar disorders
IS - 6
ER -